IMA says Coronil has no regulatory approval, Patanjali hits back 

The Indian Medical Association (IMA) has claimed that Central Drug Standard Control Organisation (CDSCO) has not given permission for the use of Coronil for the treatment of Covid-19, citing a response it received from the regulator to a Right to Information (RTI) filed. 

Another controversy has taken form for Patanjali Ayurved's Coronil, which was launched in June last year and was first advertised as a cure for the coronavirus infection but later licensed as an "immunity booster" after controversy erupted on its trial data and composition. The Indian Medical Association (IMA) has now claimed that Central Drug Standard Control Organisation (CDSCO) has not given permission for the use of Coronil for the treatment of Covid-19, citing a response it received from the regulator to a Right to Information (RTI) filed. The RTI response states: "This office has not issued any certificate or permission for the use of Coronil in treatment of COVID-19. However, as per WHO certification scheme, which is a scheme of certification pf pharmaceutical product (COPP) to M/s Divya Pharmacy Unit (II)Haridwar for their product Divya Coronil Tablet, after examination of their application in consultation with Ministry of AYUSH.